Caricamento...
T790M突变的非小细胞肺癌研究现状与前景
Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) is regarded as the main accepted first-line treatment on EGFR mutation in non-small cell lung cancer (NSCLC). Although targeted therapy for the first and two generation of TKIs may lead to longer progression...
Salvato in:
| Pubblicato in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
中国肺癌杂志编辑部
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973297/ https://ncbi.nlm.nih.gov/pubmed/28302223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.09 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|